ProfileGDS5678 / 1435048_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 66% 66% 66% 63% 65% 71% 73% 66% 65% 65% 66% 65% 66% 66% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.981366
GSM967853U87-EV human glioblastoma xenograft - Control 23.95466
GSM967854U87-EV human glioblastoma xenograft - Control 33.9572566
GSM967855U87-EV human glioblastoma xenograft - Control 43.7806463
GSM967856U87-EV human glioblastoma xenograft - Control 53.853565
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.3976971
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.6012973
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9692166
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.877165
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8918365
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.959966
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8607765
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9962266
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.969966